In Re Lupron® Marketing & Sales Practices Litigation

313 F. Supp. 2d 8, 2004 U.S. Dist. LEXIS 6564, 2004 WL 828939
District Court, D. Massachusetts·Decided April 16, 2004·No. MDL 1430; 01-CV-10861-RGS·Published·Cited by 2 cases

Opinion

MEMORANDUM AND ORDER ON DEFENDANT TAR PHARMACEUTICAL PRODUCTS INC.’S MOTION FOR CERTIFICATION OF ORDER COMPELLING DISCLOSURE OF ATTORNEY-CLIENT PRIVILEGED AND WORK PRODUCT MATERIALS FOR IMMEDIATE APPELLATE REVIEW

STEARNS, District Judge.

Defendant TAP Pharmaceutical Products, Inc. (TAP), aggrieved by the court’s Order of March 17, 2004, requiring the production of material for which it had claimed attorney-client privilege and work product protection, seeks certification of the Order for immediate appellate review *9 pursuant to 28 U.S.C. § 1292(b). By way of background, in the late 1990’s, TAP came under intense government scrutiny for the manner in which it had priced its proprietary drug Lupron®. On October 16, 2001, pursuant to a global settlement with the federal government, TAP plead guilty to violating the Prescription Drug Marketing Act, 21 U.S.C. §§ 331(t), 333(b), and paid a criminal fine of $290 million and $585 million in civil restitution. As part of the settlement, TAP and its outside counsel, the firms of Hogan & Hartson and Reed Smith, agreed to produce material to the government that had been withheld under claims of work product protection and attorney-client privilege. Prior to production, TAP received a letter from government prosecutors promising to treat the material as if protected by grand jury Rule 6(e). 1

Interlocutory certification under 28 U.S.C. § 1292(b) is appropriate when an “order [1] involves a controlling question of law [2] as to which there is substantial ground for difference of opinion and [3] that an immediate appeal from the order may materially advance the ultimate termination of the litigation.” 28 U.S.C. § 1292(b). 2 A controlling question of law, as TAP states, is one that is “ ‘serious to the conduct of the litigation, either practically or legally.’ ” Johnson v. Burken, 930 F.2d 1202, 1206 (7th Cir.1991), quoting Katz v. Carte Blanche Corp., 496 F.2d 747, 755 (3d Cir.1974). There can be no question but that the court’s determination that TAP had as a matter of law waived attorney-client privilege and work product protection by producing privileged material to the government is “serious to the conduct of the litigation.” Where TAP’s request founders is on the second leg of the § 1292(b) test, whether the court’s decision presents a “substantial ground for difference of opinion.” 3

As the court stated in the March 17 Order, it considered the “limited waiver rule” issue 4 settled in this Circuit by United States v. Massachusetts Institute of Technology, 129 F.3d 681 (1st Cir.1997) (MIT). 5 In MIT, the University made disclosures to the Defense Contract Audit Agency (DCAA), a potential adversary, and then objected when some or all of the same documents were sought by the Internal Revenue Service (IRS). In rejecting the University’s claim of a selective waiver of the attorney-client privilege, the First Circuit observed that the law had carved *10 out only a small “magic circle” of others with whom information may be shared without the loss of the privilege, specifically those persons who are necessary to facilitate the consultation between lawyer and client, such as secretaries, interpreters and counsel for co-defendants, and persons closely related to the client whose presence is appropriate, if perhaps not vital. But, “where the client chooses to share communications outside this magic circle, the courts have usually refused to extend the privilege.” Id. at 684.

In attempting to distance itself from the MIT case, TAP makes three arguments: (1) that it had explicit assurances from the government that the materials would be treated as confidential; (2) that public policy considerations favor voluntary cooperation by potential government enforcement targets to “enhanc[e] the government’s ability to conduct expeditious investigations and, where appropriate, to obtain prompt relief’; and (3) that MIT is distinguished by the fact that the secondary disclosure was to another government agency rather than to a private litigant. The first two arguments were considered and rejected in MIT.

The MIT Court addressed the reliance argument by observing that the University’s production of the disputed documents, whatever sense of security it might have derived from the DCAA’s confidentiality regulations, was nonetheless a calculated risk in light of (then) five Circuit Court opinions holding that a disclosure of privileged material to a government agency, no matter what the attendant circumstances, destroyed the privilege.

MIT may have had some reason to think that the audit agency would not disclose the documents to the IRS (and the agency did not do so). But MIT had far less reason to think that it could disclose documents to the audit agency and still maintain the privilege when IRS then sought the same documents. The choice to disclose may have been reasonable but it was still a foreseeable gamble.

Id. at 686. 6 Among the cases referenced by Judge Boudin in MIT was Judge Becker’s opinion in Westinghouse. There the disclosing client relied not only on SEC confidentiality regulations but also on a stipulated court order memorializing a secrecy agreement that it had reached with the Department of Justice (DOJ). 951 F.2d at 1426. As Judge Becker stated in rejecting the reliance argument, “[e]ven though the DOJ apparently agreed not to disclose the information, under traditional waiver doctrine a voluntary disclosure to a third party waives the attorney-client privilege even if the third party agrees not to disclose the communications to anyone else.” Id., at 1427. 7

*11 TAP’s policy argument in defense of the governmental interest in voluntary cooperation has been made in virtually every case in which the selective waiver issue has arisen. In MIT, the First Circuit, like other Circuits before it, rejected the argument as lying outside any area of judicial concern or competence. 8

Free access — add to your briefcase to read the full text and ask questions with AI

In Re Lupron® Marketing & Sales Practices Litigation, 313 F. Supp. 2d 8, 2004 U.S. Dist. LEXIS 6564, 2004 WL 828939 (D. Mass. 2004).

313 F. Supp. 2d 8 (In Re Lupron® Marketing & Sales Practices Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bailey v. United States (In re Bailey)
592 B.R. 400 (First Circuit, 2018)
In re Syncor Erisa Litigation
229 F.R.D. 636 (C.D. California, 2005)